ASCO 2016:已婚肿瘤患者生存几率明显高于未婚肿瘤患者

2016-06-11 MedSci MedSci原创

幸福的婚姻有助于增加收入,改善生活质量,消除人们的孤独感,并给予他们安全感和终身陪伴的感觉。但是,结婚对民众有促进健康的好处吗?一项新的研究表明,答案是肯定的! 结婚可以帮助民众抵抗癌症。研究结果发表在美国临床肿瘤学会年度会议(ASCO)上。 在两个研究中,研究人员发现,已婚夫妇活得更久的可能性是未婚人们的两倍。此外,由于已婚男女的稳定性生活,他们患性病的风险降低。此外,已婚民众抵抗疾病的能力更强

幸福的婚姻有助于增加收入,改善生活质量,消除人们的孤独感,并给予他们安全感和终身陪伴的感觉。但是,结婚对民众有促进健康的好处吗?


一项新的研究表明,答案是肯定的! 结婚可以帮助民众抵抗癌症。研究结果发表在美国临床肿瘤学会年度会议(ASCO)上。 

在两个研究中,研究人员发现,已婚夫妇活得更久的可能性是未婚人们的两倍。此外,由于已婚男女的稳定性生活,他们患性病的风险降低。此外,已婚民众抵抗疾病的能力更强。加利福尼亚圣地亚哥大学的研究人员指出,结婚可增加已婚肿瘤患者的生存几率。

研究人员对2000-2009年加利福尼亚肿瘤登记的相关数据进行了分析。研究人员对60000名患各种血液系统肿瘤包括白血病、淋巴瘤、多发性骨髓瘤的患者进行调查,他们发现,已婚肿瘤患者相比同疾病未婚患者而言,生存几率增加20%。未婚肿瘤患者死亡风险增加21%。 

广泛的分析记录表明,未婚的滤泡性淋巴瘤患者死亡的风险比已婚患者增加43%。未婚霍奇金淋巴瘤患者死亡风险较已婚患者增加37%。 

Matthew Wieduwilt博士指出,未婚肿瘤患者在疾病晚期进展加速,病情恶化加速,因为他们获得的支持更少,女性尤其如此。相比之下,已婚肿瘤患者获得的家庭支持和社会支持较大,这就鼓励患者继续坚持下去,鼓起战胜疾病的信心,提高治疗和服药的依从性。他们的治疗主动性得以提高,换一句话讲,他们有了活下去的理由。

因此研究人员指出,医务人员需要密切关注未婚肿瘤患者的心理社会状况,对他们多加以关心。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938591, encodeId=91c5193859152, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 18 22:14:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932545, encodeId=e55b1932545a7, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 13 00:14:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101411, encodeId=d32110141159, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101412, encodeId=74d610141232, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424160, encodeId=de801424160f6, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jun 13 08:14:00 CST 2016, time=2016-06-13, status=1, ipAttribution=)]
    2016-07-18 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938591, encodeId=91c5193859152, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 18 22:14:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932545, encodeId=e55b1932545a7, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 13 00:14:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101411, encodeId=d32110141159, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101412, encodeId=74d610141232, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424160, encodeId=de801424160f6, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jun 13 08:14:00 CST 2016, time=2016-06-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938591, encodeId=91c5193859152, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 18 22:14:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932545, encodeId=e55b1932545a7, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 13 00:14:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101411, encodeId=d32110141159, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101412, encodeId=74d610141232, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424160, encodeId=de801424160f6, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jun 13 08:14:00 CST 2016, time=2016-06-13, status=1, ipAttribution=)]
    2016-08-20 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938591, encodeId=91c5193859152, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 18 22:14:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932545, encodeId=e55b1932545a7, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 13 00:14:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101411, encodeId=d32110141159, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101412, encodeId=74d610141232, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424160, encodeId=de801424160f6, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jun 13 08:14:00 CST 2016, time=2016-06-13, status=1, ipAttribution=)]
    2016-08-20 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1938591, encodeId=91c5193859152, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Jul 18 22:14:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932545, encodeId=e55b1932545a7, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sat May 13 00:14:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101411, encodeId=d32110141159, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=101412, encodeId=74d610141232, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sat Aug 20 13:41:00 CST 2016, time=2016-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424160, encodeId=de801424160f6, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Mon Jun 13 08:14:00 CST 2016, time=2016-06-13, status=1, ipAttribution=)]

相关资讯

ASCO 2016:肿瘤药物的五大趋势

今年的美国临床肿瘤学会(ASCO)年会已经成功闭幕,我们归纳总结了一部分新数据和肿瘤药物开发的趋势,以供读者参考。 I. 肿瘤免疫疗法:PD-1组合疗法蓬勃向上 与去年ASCO年会一样,本次会议的报告集中在PD-1 / PD-L1抗体的抗肿瘤治疗方案。目前为止,PD-1受体抑制剂已在已知的每一种人类肿瘤里得以测试(见下面来自Merck的图表)。接下来的焦点逐步转移到以PD-1作为主干成分,结合

ASCO 2016:PD-1免疫疗法Keytruda治疗一系列DNA修复缺陷性肿瘤表现出持续缓解

美国制药巨头默沙东(Merck & Co)近日在2016年第52届美国临床肿瘤学会(ASCO)年会上公布了PD-1免疫疗法Keytruda(pembrolizumab)治疗存在DNA错配修复(MMR)缺陷的各类晚期癌症的更新数据。数据显示,既往已接受治疗的MMR缺陷肿瘤中,在一系列晚期非结直肠实体瘤(包括胆道、子宫内膜、胃、胰腺、前列腺、肉瘤、小肠)中的总缓解率(ORR)数据为53%(n=

Cell:挑战常规!特异性tRNA促进肿瘤转移

在任何给定的时刻,人基因组拼出上千个遗传密码单词(即密码子),这些单词告诉我们的细胞制造哪些蛋白。每个单词是由tRNA分子读取的。美国洛克菲勒大学伊丽莎白与文森特-迈耶系统癌症生物学实验室(Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology)主任Sohail Tavazoie解释道,“我们长期认为这些tRNA分子的作

EOS:减肥手术可降低肥胖者死亡风险你造么?!

在当今社会,肥胖症患者人数越来越多,肥胖已经是一个新兴的健康问题和导致死亡的重要因素。由于超重和肥胖的人越来越多,因此现在减肥手术日渐盛行。几项研究已经显示,实施减肥手术不仅可帮助患者减肥,也可增加一个人的寿命。现在更多的证据表明,减肥手术可能会大大降低肥胖民众过早死亡的风险。 最近的一项研究中,瑞典研究人员发现,肥胖的人接受减肥手术后在5年内死亡风险较低。 瑞典哥德堡大学的Christina P

Oncotarget:稳态磁场能抑制肿瘤生长

日前,中科院强磁场科学中心张欣课题组与陆轻铀课题组以及大连化物所李国辉课题组等合作,在磁场抑制肿瘤细胞生长机制以及磁场联合化疗药物抑制肿瘤细胞生长方面取得了最新进展。 近年来有实验证据表明稳态磁场能够抑制一些肿瘤细胞的生长,然而,目前此领域的研究缺乏系统性和深入性,导致磁场对肿瘤细胞的生物学效应和机制并不清楚。 科研人员通过比较不同类型的细胞在不同强度稳态磁场下的生长增殖响应,发现大多数高表达表皮

Nature子刊:单个基因就可抑制肿瘤形成!

磷酸酶-张力蛋白(Pten)是一种肿瘤抑制子,其在20%至25%的癌症患者中都处于缺失状态,近日来自梅奥诊所的研究人员通过研究发现,当细胞在分裂成为两个子代细胞的过程中,Pten可以通过维持染色体数目的完整来抵御机体肿瘤的形成,相关研究刊登于国际杂志Nature Cell Biology上。 文章中,研究者发现,通常在癌症患者机体中缺失的Pten蛋白的最后三个氨基酸对于形成完整的有丝分裂纺锤体非